October 29, 2024
With tens of millions of euros in the offing, researchers across the European Union have eagerly taken up the gauntlet to find novel interventions for difficult-to-treat […]
October 28, 2024
A novel digital treatment designed to reduce the frequency of auditory hallucinations and associated distress in patients with psychosis has been shown to be safe and […]
October 28, 2024
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to PharmaTher citing deficiencies in the company’s abbreviated new drug application for […]
October 28, 2024
The US Food and Drug Administration (FDA) has announced a voluntary manufacturer-initiated recall of more than 7000 bottles of duloxetine delayed-release capsules due to unacceptable levels […]
October 23, 2024
Home-based transcranial direct current stimulation (tDCS) with real-time remote supervision was associated with significantly greater symptom improvement and higher clinical remission rates than sham treatment in […]
October 22, 2024
Among Canadian politicians, there is a rising interest in the involuntary treatment of homeless patients with episodes of mental illness and substance abuse. Experts, however, say […]
October 18, 2024
The European Medicines Agency has recommended granting marketing authorization for a new hybrid formulation of buprenorphine as a substitution treatment of opioid drug dependence. Buprenorphine Neuraxpharm […]
October 18, 2024
A new study provides more evidence that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) used to treat diabetes and obesity could be repurposed for opioid use […]
October 17, 2024
TOPLINE: Conversion practices targeting gender identity or sexual orientation are associated with increased depression, posttraumatic stress disorder (PTSD), and suicidality in LGBTQ+ adults, a new study […]